VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31

Vistagen Therapeutics, Inc.

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.20+0.00 (+1.55%)

Close on Oct 19, 2026

Community

Notes and questions about Vistagen Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Vistagen Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Jun 7, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VTGN.

Operating margin-2784.3% · median -986.8%

Net margin-2702.6% · median -702.1%

Advertisement
300 × 250